Drugs / Lonitoclax
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07303660 | Jan → Sep 2026 expected | acute myeloid leukemia | Lomond Therapeutics Holdings, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lonitoclax | “A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients” NCT07303660 ↗ |
| Route | Oral | “Oral capsules BID” NCT07303660 ↗ |